See What HealthDay Can Do For You
Contact Us

Clinical Trials Update: June 27, 2007

Diabetes Mellitus, Type 2 Gout (Hyperuricemia) Generalized Anxiety Disorder (GAD)

(HealthDay News) -- Here are the latest clinical trials, courtesy of Thomson CenterWatch:

Diabetes Mellitus, Type 2

This study will evaluate the safety and effectiveness of an investigational drug for people with type 2 diabetes. Volunteers 18-75 may qualify who are currently taking a single diabetic medication or have not taken any diabetes medications in the past two months, and have never taken Actos, Avandia, Resulin, or Romozin.

The research site is in Jonesboro, Ark.

More information

Please see http://www.centerwatch.com/patient/studies/cat603.html.

-----

Gout (Hyperuricemia)

This study will compare the investigational drug febuxostat with allopurinol to control gout and high uric acid levels. Candidates 18-85 may be eligible if they have a history of gout, and do not have secondary hyperuricemia, a history of xanthinuria, active peptic ulcer disease, or rheumatoid arthritis.

The research site is in Lexington, Ky.

More information

Please see http://www.centerwatch.com/patient/studies/cat443.html.

-----

Generalized Anxiety Disorder (GAD)

This study will evaluate an adjunctive treatment for GAD in people who have not optimally responded to existing GAD therapies. You may qualify if you have felt anxious, nervous, worried, tense, or have trouble sleeping or concentrating. You must be at least 18 years old and be in good general health.

The research site is in Pasadena, Calif.

More information

Please see http://www.centerwatch.com/patient/studies/cat414.html.

-----

Copyright 2007 Thomson CenterWatch. All rights reserved.

Consumer News

HealthDay

HealthDay is the world’s largest syndicator of health news and content, and providers of custom health/medical content.

Consumer Health News

A health news feed, reviewing the latest and most topical health stories.

Professional News

A news feed for Health Care Professionals (HCPs), reviewing latest medical research and approvals.